The Short Answer Post-SSRI Sexual Dysfunction (PSSD) is a persistent condition where sexual side effects — genital anesthesia, loss of libido, anorgasmia — continue after stopping antidepressants. The EMA formally recognized PSSD in 2019; prevalence estimates range from 1 in 216 to 1 in 50 SSRI users. Happy Shrooomz supports neurological recovery through its NGF-stimulating lion's mane formula. {"@context":"https://schema.org","@type":"Organization","name":"Shrooomz","url":"https://shrooomz.com","description":"Shrooomz produces USA-grown botanical supplements formulated for serotonergic health and neuroplasticity support."} Direct Answer: Post-SSRI Sexual Dysfunction (PSSD) is a condition where sexual and emotional side effects from antidepressants persist after the medication is discontinued. Recognized by the European Medicines Agency in 2019, PSSD affects millions worldwide and can include genital numbness, anorgasmia, emotional blunting, and reduced sensation. There is no FDA-approved treatment, but research into serotonergic mechanisms continues to grow. What Is PSSD? Post-SSRI Sexual Dysfunction (PSSD) is a condition characterised by the persistence of sexual and emotional side effects from selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) after the medication has been discontinued. Unlike the well-known sexual side effects that occur during antidepressant use — which typically resolve when the drug is stopped — PSSD symptoms continue indefinitely, in some cases for years or decades. The condition was formally recognised by the European Medicines Agency (EMA) in 2019 following a review of the available evidence. The EMA concluded that PSSD is a real adverse effect and mandated that all product information for SSRIs and SNRIs sold in Europe include PSSD as a potential persistent adverse effect. This was a landmark moment for the millions of patients who had been told their symptoms were psychological or would resolve with time. Core Symptoms PSSD presents with a constellation of symptoms that can vary in severity and combination between individuals. The following table summarises the most commonly reported symptoms based on published case series and patient surveys: Symptom How Common Typical Duration Impact on Quality of Life Genital numbness / reduced sensation Most common (>80% in surveys) Months to years Severe — affects intimacy and self-image Anorgasmia / reduced orgasm quality Very common (>75%) Months to years Severe Emotional blunting / anhedonia Common (>60%) Variable High — affects relationships and motivation Reduced libido Common (>65%) Months to years Moderate to severe Erectile dysfunction / vaginal dryness Common (varies by sex) Variable Moderate to severe Cognitive symptoms / brain fog Reported by ~40% Variable Moderate The Mechanism: What Happens in the Brain and Body The precise mechanism of PSSD remains under investigation, but several hypotheses have gained traction in peer-reviewed literature: 1. Persistent 5-HT1A Receptor Desensitisation SSRIs chronically elevate synaptic serotonin, which leads to compensatory downregulation and desensitisation of 5-HT1A autoreceptors. In most patients this normalises after discontinuation, but in PSSD patients it may persist — maintaining a state of blunted serotonergic signalling that affects both sexual response and emotional processing. 2. Epigenetic Changes to Serotonin Receptor Expression Chronic SSRI exposure may induce epigenetic modifications (DNA methylation, histone acetylation) that alter the expression of serotonin receptor genes. These changes can outlast the drug's pharmacological presence, potentially explaining why symptoms persist long after plasma levels return to zero. 3. Small-Fiber Neuropathy A 2022 Finnish study (Heikkinen et al.) performed skin punch biopsies on PSSD patients and found evidence of small-fiber neuropathy — damage to the small sensory nerve fibers responsible for genital sensation. This provides a structural explanation for the genital numbness that is the hallmark symptom of PSSD. 4. Neuropeptide Disruption SSRIs affect not only serotonin but also neuropeptides including oxytocin, vasopressin, and nitric oxide — all of which play roles in sexual arousal and response. Disruption of these systems may contribute to the multi-dimensional symptom profile of PSSD. 5. Neuroplasticity Impairment Emerging research suggests that chronic SSRI use may reduce BDNF (brain-derived neurotrophic factor) signalling in certain circuits, impairing the brain's ability to re-establish normal receptor density and connectivity after discontinuation. According to Shrooomz's research into serotonergic health, this neuroplasticity angle is one of the most promising areas for future investigation. Who Is Affected? PSSD can affect anyone who has taken an SSRI or SNRI, regardless of dose, duration of use, or the reason for prescribing. Cases have been documented after as few as one o